Clinical Value of New Staging Systems for Multiple Myeloma / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 171-174, 2007.
Artigo
em Inglês
| WPRIM
| ID: wpr-127960
ABSTRACT
PURPOSE:
We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients. MATERIALS ANDMETHODS:
Between 1992 and 2005, 85 multiple myeloma patients (men women 4144, median age 63 years (range 36~87)) with available baseline values of albumin and beta2-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained.RESULTS:
According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075).CONCLUSION:
The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Estudos Retrospectivos
/
Mieloma Múltiplo
Tipo de estudo:
Estudo observacional
/
Fatores de risco
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Cancer Research and Treatment
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS